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ABSTRACT
Objectives There have been reports of patients with
antibodies to neuronal antigens misdiagnosed as
sporadic Creutzfeldt-Jakob disease (sCJD). Conversely,
low levels of antibodies to neuronal proteins have been
reported in patients with sCJD. However, the frequency
of misdiagnoses, or of antibodies in patients with
subsequently conﬁrmed sCJD, is not clear.
Methods We reviewed 256 consecutive cases of sCJD
seen in the National Prion Clinic, of whom 150 had sera
previously referred for selected antibody tests. Eighty-two
available samples were retested for antibodies to
N-methyl-D-aspartate receptor (NMDAR), the glycine
receptor (GlyR), voltage-gated potassium channel
(VGKC)-complex and the associated proteins, leucine-rich
glioma inactivated 1 (LGI1) and contactin-associated
protein 2 (CASPR2).
Results Four of the initial 150 sera referred were
positive; two had antibodies to NMDAR, and two to the
VGKC-complex, one of which was also positive for GlyR
antibodies. Of the 82 sCJD sera retested, one had
VGKC-complex antibodies conﬁrming the previous result,
two had CASPR2 and GlyR antibodies and one had
CASPR2 and NMDAR antibodies; all antibodies were at
low levels. Over the same period three patients with
autoimmune encephalitis and high VGKC-complex
antibodies were initially referred as sCJD.
Conclusions This study indicates that <5% patients
with sCJD develop serum antibodies to these neuronal
antigens and, when positive, only at low titres. By
contrast, three patients referred with possible prion
disease had a clinical picture in keeping with
autoimmune encephalitis and very high VGKC-complex/
LGI1 antibodies. Low titres of neuronal antibodies occur
only rarely in suspected patients with sCJD and when
present should be interpreted with caution.
INTRODUCTION
Autoantibodies to speciﬁc neuronal proteins are
associated with encephalopathies1 2 but these can
share clinical features, such as cognitive decline,
personality changes and movement disorders, with
Creutzfeldt-Jakob disease (CJD).3 There have been
several case reports and two studies3 4 that
included patients whose diagnosis of
immunotherapy-responsive limbic encephalitis was
delayed because of a suspected diagnosis of CJD.
Conversely, there have been occasional reports of
patients presenting with encephalopathy and low
levels of serum antibodies to neuronal protein such
as the N-methyl-D-aspartate receptor (NMDAR),
voltage-gated potassium channel complex
(VGKC-complex) or glycine receptor (GlyR), who
were later conﬁrmed to have sporadic CJD
(sCJD).5–7
Although the absence of NMDAR antibodies in
346 referred cerebrospinal ﬂuid (CSF) samples,
including samples from 49 conﬁrmed sCJD cases4
was reported recently, the frequency of
disease-relevant serum antibodies in patients with
sCJD prior to diagnosis, and how frequently an
incorrect CJD diagnosis could have been averted,
have not been studied systematically. Here we
report antibody testing in patients seen in the
National Prion Clinic, to which all cases of sus-
pected prion disease in the UK are referred. We
determined the number of samples sent for anti-
body testing prior to referral, and then tested or
retested all available sera for the most relevant anti-
bodies. Our results indicate that antibodies detected
in patients with subsequently-conﬁrmed sCJD are
rare and only present at low levels that may not be
clinically relevant. We contrast these cases with
three patients examined during the same period
whose eventual diagnosis was deﬁnite autoimmune
encephalitis, supported by high titres of
VGKC-complex/LGI1 antibodies.
METHODS
Since 2004 all patients in the UK with suspected
CJD have been referred jointly to the National
Prion Clinic in London and to the National CJD
Research and Surveillance Unit in Edinburgh. From
2008, a subset of these patients was recruited into
the National Prion Monitoring Cohort, a study
designed to determine the natural history of all
types of CJD. By June 2013, a total of 486 patients
were documented. A total of 456 of these patients
were considered to have clinically probable or def-
inite CJD8 comprising 256 with sCJD, 9 with
variant CJD, 12 with iatrogenic CJD due to treat-
ment with contaminated human pituitary-derived
growth hormone and 167 symptomatic or at-risk of
inherited prion disease. The remainder had a
variety of other, mainly neurodegenerative, condi-
tions, including three with autoimmune
encephalitis.
Review of the 256 cases of probable or deﬁnite
patients with sCJD identiﬁed 150 patients for
whom serum had been sent to the Clinical
Neuroimmunology service in Oxford for a variety
of individual antibody assays. No CSF samples had
been sent. After compiling the results of all diag-
nostic tests requested, we retrieved the 82 sera still
available in order to screen or rescreen for
neuronal antibodies. Antibodies to NMDAR,
GlyR, LGI1 and CASPR2 were detected by
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demonstrating antibody-binding to human embryonic kidney
cells transfected with complementary DNA encoding the differ-
ent antigens, as used in the diagnostic service.9–14 VGKC-
complex antibodies were determined by immunoprecipitation of
125I-α-dendrotoxin-labelled rabbit whole brain extract as also
used for diagnosis.13 All results were assessed independently by
two observers, and positive results were repeated at different
dilutions when sufﬁcient sample was available.
RESULTS
Referred samples
Neurologists around the UK had requested a total of 305 diag-
nostic antibody tests for 150 of the 256 patients with sCJD
(59%) before referral to the National Prion Clinic. The most
commonly requested tests were for VGKC-complex, NMDAR
and paraneoplastic antibodies (table 1). Of the 150 sera, two
were reported as low positive for NMDAR antibodies and two
were positive or low positive for VGKC-complex antibodies. The
latter patient was also low positive, then positive, for GlyR anti-
bodies.7 The results and normal ranges are given in the table 1.
The remaining 146 sera were negative for all requested tests,
including antibodies against paraneoplastic antigens, the
P/Q-type voltage-gated calcium channel (VGCC) and NMDAR
(see table 1).
Retrieved samples
Sera from 82 of the patients were still available and were system-
atically tested for serum antibodies to NMDAR, GlyR,
VGKC-complexes and the associated proteins LGI1 and
CASPR2. Four patients (5%) tested positive. One had
VGKC-complex antibodies (conﬁrming the previous requested
test). Three had CASPR2 antibodies, two of these were also
positive for GlyR antibodies, and one also had NMDAR anti-
bodies. LGI1 antibodies were not found in any sera. The results
are detailed in table 1.
All patients with sCJD with positive antibodies
Between the referred samples and retrieved samples, there were
seven patients with sCJD with one or more antibodies detected
(<5%, table 1). Details of the patients’ clinical presentations
and investigations are given in online supplementary table S1.
Their mean age was 68 years and the mean duration was 203
(59–401) days compared to a mean age of 67 years and mean
duration of 242 (27–2387) days in the 249 patients with sCJD
for whom no antibodies were detected.
Samples referred from patients with encephalitis
Over the same period of time three additional patients, referred
to the National Prion Clinic with a provisional diagnosis of
sCJD, were considered more likely to have autoimmune enceph-
alitis. Each had high VGKC-complex antibody titres when
tested (>5000 pM, table 1) and two had demonstrated speciﬁ-
city for LGI1. The clinical details are given in online supple-
mentary table S2. One female was treated successfully with a
rapid fall in VGKC-complex antibodies and made a complete
recovery, but the two males died within a month of testing
without treatment.
Postmortem results
Of the 249 patients who died, 139 had postmortem brain exam-
inations. The diagnosis of CJD was conﬁrmed in all. The diag-
nosis of encephalitis was conﬁrmed in the one patient with high
titres of VGKC-complex antibodies who had an autopsy.
DISCUSSION
There can be diagnostic confusion at the onset of sCJD. One
important immunotherapy-responsive disease that needs to be
excluded is VGKC-complex antibody positive limbic encephal-
itis.3 4 Other immune-mediated diseases may be suspected
depending on the clinical features. A high proportion of patients
with eventual sCJD diagnosis (150/256; 59%) had sera referred
for speciﬁc antibody assays, the requested tests presumably
reﬂecting their clinical features at presentation. The number of
positive results, however, was low, with NMDAR or
VGKC-complex antibodies present in only four patients (<5%)
and no other antibodies detected at that time. When
Table 1 Antibodies found in patients with sCJD or limbic
encephalitis
150 Sera referred pre-sCJD
diagnosis (n=number tests
requested)
Positive (% tested)
Antibody scores or titres*
VGKC-complex (n=119) 2 (1.7%); 210 pM, 113 pM
NMDAR (n=77) 2 (2.6%); both low positive at 1:20
Paraneoplastic (n=51) 0
VGCC (n=25) 0
GAD (n=16) 0
GlyR (n=6) 1; low positive initially, rising to
positive at 1:20; Also VGKC-complex
210 pM
Ganglioside (n=5) 0
MuSK (n=3) 0
AQP4 (n=2) 0
MOG (n=1) 0
MAG (n=1) 0
Total positive sera 4/150 (2.7%)
82 sCJD Sera available for retrospective
analysis†
VGKC-complex 1 (1.2%), confirmed previous
requested result
NMDAR 1 (1.2%) low positive at 1:20
GlyR 2 (2.4%), positive at 1:20; and
positive 1:100
CASPR2 3 (3.6%) low positive at 1:100,
positive at 1:200 and 1:400; each
positive for NMDAR (n=1) or GlyR
(n=2) antibodies as above
LGI1 0
Total positive sera 4/82 (4.9%)
Referred after admission to the National
Prion Clinic as probable sCJD. Final
diagnosis limbic encephalitis
VGKC-complex 3 (3.6%) >5000 pM, two LGI-Ab
positive (titres not determined), one
untested.
One female given immunotherapy
recovered, two untreated males died
*Details of the patients with positive antibody tests are included in the online
supplementary tables. The screening assays were performed as for all routine samples
at 1:20 (NMDAR, GlyR) or 1:100 (CASPR2) and the reports based on visual binding
scores of 0 (negative), 1–4 (positive with increasing intensity). Low positive at 1:20
(or 1:100 for CASPR2) infers a score of 1.5; positive infers >1.5. Titres are based on
further dilutions of serum until the endpoint dilution which gives a score of 1. Normal
values based on healthy and disease controls are <1:20 for NMDAR, LGI1 and GlyR
and <1:100 for CASPR2.12–14
†All sCJD sera available; postmortem-confirmed n=42; postmortem not performed
n=40.
AQP4, aquaporin-4; CASPR2, contactin-associated protein 2; GAD, glutamic acid
decarboxylase; GlyR, glycine receptor; LGI1, leucine-rich glioma inactivated 1; MAG,
myelin-associated glycoprotein; MOG, myelin oligodendrocyte glycoprotein; NMDAR,
N-methyl-D-aspartate receptor; sCJD, sporadic Creutzfeldt-Jakob disease; VGCC,
voltage-gated calcium channel; VGKC, voltage-gated potassium channel complex.
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systematically testing all 82 available sera for NMDAR, GlyR
and VGKC-complex antibodies, only 4 (3 additional) were posi-
tive (5%) and mostly at relatively low levels; but, during the
same period of time, three other patients were identiﬁed with
high VGKC-complex antibodies (>400 pM). Although two of
these died before treatment could be initiated, the remaining
patient recovered with immunotherapy. We can therefore con-
clude that while VGKC-complex or NMDAR antibodies are not
a common feature of sCJD, they can be present in rare cases at
levels unlikely to be of clinical relevance, as indicted by other
studies.9–12 Higher levels of these antibodies, by contrast, are
very likely to be associated with an alternative autoimmune
diagnosis. It remains important, therefore, to consider auto-
immune encephalitis in the differential diagnosis and to test for
the relevant antibodies.
Reassuringly, a high proportion of patients were investigated
for possible paraneoplastic or autoimmune forms of encephalitis
during their presentation. In spite of this, high levels of
VGKC-complex antibodies in two patients were not detected
early enough during disease progression. It is important for clin-
icians to be aware of clinical features that are atypical in sCJD
presentation (see online supplementary table S2), such as facio-
brachial seizures and autonomic dysfunction, which may indi-
cate an autoimmune disorder. This is particularly relevant if the
MRI does not show the typical features of prion disease on dif-
fusion sequences. Furthermore, too much reliance on non-
speciﬁc markers of degeneration in CSF such as 14.3.3 and
S100B proteins, positive in both tested encephalitis patients (see
online supplementary table S2), can result in an incorrect diag-
nosis. However, a high positive VGKC-complex Ab (LGI1-Ab
negative) was recently identiﬁed in a patient with a new
Gerstmann-Straüssler-Scheinker mutation who did not respond
to immunotherapies and subsequently died.15
None of the patients had CSF referred for testing, likely
because the Oxford assays do not require CSF for diagnostic
testing and also due to the perceived potential risk with CSF
from possible sCJD cases. The recent study of 300 CSF
samples, including 49 from patients with deﬁnite sCJD from the
Barcelona Centre4 found that all sCJD samples were negative
for NMDAR antibodies. However, given that concentrations in
the CSF are lower than that of serum, they could be difﬁcult to
detect in patients with the low concentrations reported here.
The reason for the occasional presence of serum antibodies at
low levels in sCJD is unclear. It is possible that they occur as a
result of extensive and rapid neuronal destruction, as suggested by
a case of sCJD where both VGKC-complex and glycine receptor
antibodies were identiﬁed (case 1, see supplementary table S1).7 In
this case improvement after immunotherapy was apparent, though
not sustained. Some improvement in cognitive function was also
observed in case 3 after the patient underwent a trial of immuno-
therapy (see supplementary table S1). These cases raise the possi-
bility that the autoantibodies identiﬁed in patients with sCJD,
although unlikely to be primarily pathogenic in patients with a
neurodegenerative disorder, may sometimes contribute to the clin-
ical manifestations during the disease process. Further studies on
autoantibody levels during the course of sporadic and genetic
forms of prion disease, and whether the antibodies contribute to
the disease pathophysiology, could provide insight into the
complex role of autoantibodies in neurodegenerative diseases.
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